Abstract
The Omicron variant of severe acute respiratory syndrome coronavirus 2 has multiple amino acid mutations in its spike proteins, which may allow it to evade immunity elicited by vaccination. We examined the neutralising activity and S1-IgG titres in patients with breakthrough infections caused by the Omicron variant after two doses of vaccination. We found that neutralising activity was significantly lower for the Omicron variant than for the Wuhan strain. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant.
Keywords: Antibody titre; Breakthrough infection; Coronavirus disease 2019 (COVID-19); Neutralising activity; Omicron.
All Keywords
【저자키워드】 Coronavirus disease 2019 (COVID-19), Breakthrough infection, Omicron., Antibody titre, Neutralising activity, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, coronavirus, vaccination, Mutation, Immunity, variant, severe acute respiratory syndrome Coronavirus, omicron, Patient, breakthrough infections, Omicron variant, Breakthrough infection, respiratory, Antibody titre, Neutralising activity, Amino acid, dose, Spike proteins, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, titre, Wuhan strain, significantly lower, examined, caused, induce, evade, elicited, 【제목키워드】 variant, Patient, Japan, the SARS-CoV-2,
【저자키워드】 Coronavirus disease 2019 (COVID-19), Breakthrough infection, Omicron., Antibody titre, Neutralising activity, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, coronavirus, vaccination, Mutation, Immunity, variant, severe acute respiratory syndrome Coronavirus, omicron, Patient, breakthrough infections, Omicron variant, Breakthrough infection, respiratory, Antibody titre, Neutralising activity, Amino acid, dose, Spike proteins, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, titre, Wuhan strain, significantly lower, examined, caused, induce, evade, elicited, 【제목키워드】 variant, Patient, Japan, the SARS-CoV-2,
{{{ 추상적인 }}}
중증급성호흡기증후군 코로나바이러스 2의 오미크론 변종은 스파이크 단백질에 다중 아미노산 돌연변이가 있어 백신 접종으로 유발되는 면역을 피할 수 있습니다. 우리는 두 번의 백신 접종 후 Omicron 변이에 의한 돌발성 감염 환자에서 중화 활성과 S1-IgG 역가를 조사했습니다. 우리는 중화 활성이 우한 균주보다 오미크론 변이체에 대해 상당히 낮음을 발견했습니다. 두 번의 백신 접종은 Omicron 변이체에 대한 충분한 중화 활성을 유도하지 않을 수 있습니다.
{{ 키워드: }} 항체 역가; 획기적인 감염; 코로나바이러스 질병 2019(COVID-19); 중화 활성; 오미크론.